濟川藥業 (600566.SH): 第三季度業績高速增長 October 30, 2017

投資概要

濟川藥業公佈第三季度業績報告,公司實現分別營業收入和淨利潤同比21.75%、38% 的高增長。我們預計未來收入的增長主要受三個因素驅動:核心產品納入更多省級醫 保;銷售網路擴張,加強OTC市場的開拓;可持續的產品儲備。我們預計2017、2018 年營業收入的增長率分別為22%、18%,提高我們的目標價到45.70元人民幣,給予“增 持”評級。(現價截至10月26日)

About the author

Profile photo of Eurus Zhou

Eurus Zhou
Phillip Securities (HK)

Graduated from Hong Kong Polytechnic University, Master of Finance (Investment Management). Possess bachelor degree majoring in Financial Management from Southwestern University of Finance and Economics. Focus on industry prospect and corporate fundamentals to explore investment value and cover pharmaceutical and consumer industry.

Get access to all the latest market news, reports, technical analysis
by signing up for a free account today!